Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesNew Avatec Plus 3-Nitro Combination-Use Approval Now Brings Turkey Growers the Only Ionophore-Based Coccidiosis Control with the Performance of 3-Nitro
King Pharmaceuticals, 06/24/09
Turkey growers can now capitalize on feeding an ionophore in combination with 3-Nitro, thanks to a new feed additive combination-use approval to medicate feed containing both Avatec and 3-Nitro. In late May, the U.S. Food and Drug Administration approved Alpharma Animal Health's application to combine the two products for turkeys. The approval permits use of Avatec at 68 to 113 grams of lasalocid per ton of feed in combination with 3-Nitro at 22.7 to 45.4 grams of roxarsone per ton of feed.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Today in Drug Interactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials
BMC Infectious Diseases, 12/03/09
Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children
Malaria Journal, 12/01/09
Pharmacokinetic—pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide
Clinical Therapeutics, 12/01/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
Shire, 12/03/09
Allos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN
Allos Therapeutics, 12/01/09
Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Archives of Neurology, 11/23/09
Sponsor
Article Search
Sponsor